Pastoureau P, Vergnaud P, Meunier P J, Delmas P D
INSERM Unit 234, Hôpital Edouard Herriot, Lyon, France.
J Bone Miner Res. 1993 Dec;8(12):1417-26. doi: 10.1002/jbmr.5650081202.
The physiologic role of osteocalcin (OC), a vitamin K-dependent protein specific to bone, remains elusive. It has been shown that rats maintained on chronic treatment with vitamin K1 and its antagonist warfarin exhibit a marked decrease in bone osteocalcin because noncarboxylated osteocalcin does not bind to bone hydroxyapatite. To assess the role of OC in bone remodeling, we applied the warfarin model to growing lambs. We analyzed the bone changes after 3 months of concurrent warfarin and vitamin K1 treatment. Four groups of four lambs were constituted at birth and received daily a saline solution (control group, CT), 4 mg/kd/day of vitamin K1 (vitamin K group), 4 mg/kg/day of vitamin K1 + 75 or 150 mg/kg/day of warfarin (W75 and W150 group, respectively). In warfarin-treated animals, bone osteocalcin levels were decreased, both in the metaphysis (9% compared to controls) and the diaphysis (30% compared to controls) of the metacarpals. The fraction of noncarboxylated osteocalcin measured every month in the serum was significantly higher in warfarin-treated lambs than in controls at each timing point (37.6 +/- 2.6% in W75 and 48.7 +/- 5.2% in W150 versus 14.4 +/- 3.8% in controls at 3 months). Compared to non-warfarin-treated animals (NW), the main histomorphometric parameters measured on the iliac crest after tetracycline double labeling were significantly reduced in the warfarin-treated lambs: 12.2 +/- 5.2 versus 18.6 +/- 4.7% in NW (p < 0.03) for the cancellous bone area, which reflects the trabecular bone density; 14.7 +/- 6.1 versus 21.0 +/- 3.6% in NW (p < 0.03) for the eroded perimeter, and 0.315 +/- 0.064 versus 0.561 +/- 0.23 microns 3/microns 2/day in NW (p < 0.02) for the tetracycline-based bone formation rate. In conclusion, the depletion of osteocalcin in the bone of lambs induced within 3 months a marked osteopenia that resulted from a decrease in resorption and a more pronounced decrease in bone formation. Our data suggest that the presence of osteocalcin, the major gla-containing protein of bone, may be important for the maintenance of a normal bone mass and remodeling of trabecular bone.
骨钙素(OC)是一种骨特异性的维生素K依赖蛋白,其生理作用仍不清楚。研究表明,长期用维生素K1及其拮抗剂华法林治疗的大鼠骨骨钙素显著降低,因为非羧化骨钙素不与骨羟基磷灰石结合。为了评估OC在骨重塑中的作用,我们将华法林模型应用于生长中的羔羊。我们分析了华法林和维生素K1联合治疗3个月后的骨变化。四组羔羊在出生时每组四只,分别每日接受生理盐水(对照组,CT)、4mg/kg/天的维生素K1(维生素K组)、4mg/kg/天的维生素K1 + 75或150mg/kg/天的华法林(分别为W75和W150组)。在接受华法林治疗的动物中,掌骨的干骺端(与对照组相比降低9%)和骨干(与对照组相比降低30%)的骨骨钙素水平均降低。在每个时间点,接受华法林治疗的羔羊血清中每月测得的非羧化骨钙素比例均显著高于对照组(3个月时,W75组为37.6±2.6%,W150组为48.7±5.2%,而对照组为14.4±3.8%)。与未接受华法林治疗的动物(NW)相比,在四环素双重标记后在髂嵴上测得的主要组织形态计量学参数在接受华法林治疗的羔羊中显著降低:反映小梁骨密度的松质骨面积,NW组为18.6±4.7%,而华法林治疗组为12.2±5.2%(p<0.03);侵蚀周长,NW组为21.0±3.6%,而华法林治疗组为14.7±6.1%(p<0.03);基于四环素的骨形成率,NW组为0.561±0.23微米³/微米²/天,而华法林治疗组为0.315±0.064微米³/微米²/天(p<0.02)。总之,羔羊骨中骨钙素的耗竭在3个月内导致了明显的骨质减少,这是由于吸收减少和骨形成更显著减少所致。我们的数据表明,骨钙素作为骨中主要的含γ-羧基谷氨酸蛋白,其存在可能对维持正常骨量和小梁骨重塑很重要。